Jessica Wu

Jessica Wu is a Taiwan-based finance and biopharma executive. TWi Biotechnology lists her as Chairman and gives her prior roles as Director of TWi Pharmaceuticals, Senior Advisor at Xinchen Investment, Head of International Investment Banking and Executive Vice President at KGI Securities, President of Prudence Capital Management, President of Global Financial Services, Vice President and Chief Representative in Beijing for Lehman Brothers Asia, and Assistant Vice President at Chase Manhattan Bank’s Taipei branch.

Her education includes an M.A. in Economics from Indiana University and a B.B.A. from National Taiwan University, according to TWi Biotechnology’s board profile. A 2025 Global Bio & Investment Monthly profile says she has more than 35 years of experience across commercial banking, investment banking, and venture capital, spanning Taiwan, Hong Kong, mainland China, and Southeast Asia.

Before TWi Biotechnology, Wu was associated with Prudence Capital Management, manager of the Prudence Venture Capital Fund. The fund was established in August 2001, had NT$2 billion in fund size, and targeted optoelectronics, telecommunications/networking, IT/software, semiconductors, biotechnology, MEMS, novel materials, and fuel cells, with a focus on Taiwan and the Greater Pacific Basin.

At TWi Biotechnology, Wu chairs a clinical-stage biopharma company developing drug-repurposing and 505(b)(2) programs for dermatological, CNS, and rare diseases. In 2025, she helped lead TWi’s merger with DuKang Pharmaceuticals, adding NORA520, an oral prodrug of brexanolone for postpartum depression and major depressive disorder, to TWi’s pipeline.

• Prudence Venture Capital Fund’s disclosed strategy was broad-stage investing: seed, startup, expansion, and mature-stage opportunities.
• Sector focus at Prudence centered on Taiwan’s technology and life-sciences economy: optoelectronics, telecom/networking, IT/software, semiconductors, biotechnology, MEMS, novel materials, and fuel cells.
• Geographic focus was Taiwan and the Greater Pacific Basin.
• Wu’s current company-building focus at TWi is on drug repurposing and 505(b)(2) development for high-unmet-need diseases, especially dermatology, rare diseases, and CNS disorders.
• Wu’s own stated 2025 rationale for the TWi-DuKang merger was that the companies were complementary, one focused on rare dermatological diseases and the other on neuropsychiatric disorders, and that combining them would expand the pipeline, create operational synergies, diversify risk, and enhance shareholder value.
• In a 2025 interview, Wu said 2026 would enter a licensing peak period and that completion of global licensing for any core asset could support TWi’s path toward a public listing by the end of 2027.